Phase 2 Initiation Targeted for Second Half of 2025 Overview of key poster abstracts Hanmi will present at ADA 2025 (Source: Hanmi Pharmaceutical homepage) (June 10, 2025) Hanmi Pharmaceutical is set to unveil a series of breakthrough research results on its next-generation, game-changing obesity drug candidates that overcome the inherent limitations of GLP-1-based therapies, including inevitable muscle loss, at one of the worlds most prestigious metabolic disease conferences
Dose and injection tracking Pep sends personalized reminders for Ozempic, Wegovy, Mounjaro, Zepbound, compounded shots, and oral GLP-1 pills
With increased blood flow to the brain and the cardiovascular system, less blood flow is directed to the gastrointestinal tract
Track your intake for one to two weeks to establish your baseline
If it persists beyond 8 weeks, discuss with your provider about dose adjustment or formulation change
People who smoke and qualify for these drugs might benefit the most from getting them
